June 17th, 2024

Transfer of Argatroban Business in Europe
Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative
Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi ChemicalGroup, announced has entered into an agreement with Ethypharm (Saint Cloud, Paris;CEO: Denis Delval) on June 13th 2024 for the transfer of business of the selective
antithrombin agent, argatroban monohydrate (argatroban) in Europe.
Under MTPC's strategic focus on Radicava (generic name: edaravone), treatment agent
for amyotrophic lateral sclerosis, within its European operations, it has been decided totransfer the argatroban business to Ethypharm.
In Europe, MTPC’s subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referredto as "MTPE," located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi
Tanabe Pharma GmbH (hereinafter referred to as "MTPD," located in Duesseldorf,Germany), have been actively involved in the marketing and sales of argatroban in United
Kingdom and Germany, among other European countries, through their respective
networks of partners.
Ethypharm, known for its expertise in Europe in essential drugs in the field of CNS diseases(severe pain and addiction) and Hospital Injectables, aims to strengthen its establishedpharmaceutical business in Europe through the acquisition of MTPC group's Europeanargatroban business. Furthermore, it intends to contribute to meeting the healthcare needsof various European countries through the provision of argatroban supply.
MTPC group remains committed to delivering pharmaceutical products to patients inEurope through MTPE and MTPD, including the continued supply of Radicava. etc.,
thereby making a meaningful contribution to those facing diseases in the region.

Contact:
Mitsubishi Chemical Group Corporation
Communications Division
Osaka Communications Department+81-6-6205-5119

1/2

■About Argatroban:
Argatroban is a selective antithrombin agent developed by MTPC and is currently marketedin Japan under the name "Novastan." In Europe, it first received approval in Sweden in2004 and is presently available as a treatment for heparin-induced thrombocytopenia (HIT)
type II in 13 countries, including Germany, United Kingdom, France, Spain and Italy.
"Heparin-induced thrombocytopenia (HIT) type II " is a severe condition that carries the riskof fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-lifein the bloodstream and undergoes metabolism in the liver, making it suitable for patients
post-surgery and those with kidney disease who may develop HIT type II.
■About Ethypharm:
Ethypharm is a leading mid-sized international pharmaceutical company, with strong
European roots, that manufactures and provides essential drugs, with a focus on hospitalcare, central nervous system (severe pain and addiction) and internal medicine. Its
commitment is to improve patients’ lives and make a positive impact on society and theenvironment. Ethypharm has 1,700 employees dedicated to its various pharmaceuticalactivities, of which 1,400 are in industrial operations. The six production sites located inFrance, the UK, Spain, and China have expertise in injectables and complex oral solidforms.

2/2